ASCO Gastrointestinal Cancer Symposium | Conference

Lenvatinib Yields Survival Benefit, Manageable Toxicities in Recurrent HCC After Liver Transplantation
January 24, 2022

Patients with recurrent hepatocellular carcinoma after liver transplantation were treated with lenvatinib and saw promising efficacy.

Adding Nivolumab to SOC Fails to Extend PFS in Metastatic CRC
January 23, 2022

The CheckMate 9X8 trial did not hit the primary end point of progression-free survival superiority with nivolumab plus standard of care vs standard of care alone in metastatic colorectal cancer.

ctDNA Assays Identify Resectable CRC Likely to Benefit Adjuvant Chemotherapy
January 23, 2022

The observational GALAXY study found that use of a ctDNA assay could help determine which patients with colorectal cancer stand to benefit the most by receipt of adjuvant chemotherapy.

Trastuzumab Deruxtecan Shows Encouraging Efficacy for HER2+ Metastatic Colorectal Cancer
January 23, 2022

Treatment with trastuzumab deruxtecan produced promising efficacy results for patients with HER2-positive metastatic colorectal cancer.

Encorafenib, Cetuximab, and Nivolumab Induced Responses and was Tolerable in MSS, BRAFV600E-Mutated Metastatic CRC
January 22, 2022

Results from a phase 1/2 study showed that a combination of encorafenib, cetuximab, and nivolumab was well tolerated and yielded promising responses in patients with microsatellite stable BRAFV600E metastatic colorectal cancer.

Regorafenib Plus Pembrolizumab Combo Misses PFS End Point, Shows Strong OS for MSS Colorectal Cancer
January 22, 2022

Although the combination of regorafenib and pembrolizumab failed to meet significance for progression-free survival, an improvement in overall survival and disease control were observed for patients with microsatellite stable colorectal cancer.

Pembrolizumab Combo Yields Durable Response in Treatment-Refractory mCRC
January 22, 2022

Pembrolizumab, binimetinib , and bevacizumab led to deep and durable responses for patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer.

Tolerable Safety Profile Seen With Onvansertib Combo in KRAS-Mutant mCRC
January 22, 2022

Patients with KRAS-mutant metastatic colorectal cancer who were treated with a combination containing onvansertib had a tolerable safety profile.

Lenvatinib/TACE May Be Efficacious, Safe as First-Line Treatment for Advanced HCC
January 22, 2022

Patients with advanced hepatocellular carcinoma achieved notable improvements in survival and responses following treatment with transarterial chemoembolization and lenvatinib.

Olaparib Plus Pembrolizumab Treatment Safe in Advanced Chloangiocarcinoma
January 22, 2022

Interim results of a phase 2 trial found a safe toxicity profile for olaparib plus pembrolizumab in advanced cholangiocarcinoma.